Articles tagged with Head and Neck Cancer
A multicenter trial demonstrated that Taxotere in combination with cisplatin and 5-FU prolonged progression-free survival by 12.7 months compared to the standard treatment. Patients also showed significantly improved overall response rates, indicating a potential new paradigm for treating head and neck cancer.
A study identified four tumor gene expression patterns that may serve as biomarkers of prognosis for head and neck squamous cell cancer patients. The patterns were associated with different outcomes, including the worst outcome linked to epidermal growth factor pathway activation, and a tobacco exposure signature.
A new study found that infection with a high-risk type of human papillomavirus (HPV) in oral epithelial cells may be an independent risk factor for head and neck cancer. High-risk HPV types detected in oral exfoliated cells were predictive of high-risk HPV types in tumor tissue.
Researchers have discovered several protein profiles that are present more commonly in patients with HNSCC than in healthy smokers or control patients, enabling accurate diagnosis. The newly developed technology could potentially lead to the development of a reliable screening test for early detection and diagnosis of HNSCC.
A new trial has shown that faster radiotherapy can improve head and neck cancer treatment outcomes, with a 60-70% benefit in tumour control and better voice conservation. The study found that accelerated treatment was linked to high EGFR expression and good tumour differentiation.
A randomised controlled trial found that accelerated radiotherapy improved five-year tumour control by 10% compared to standard radiotherapy, with benefits also seen in patients with laryngeal cancer. The treatment was associated with a small increase in disease-specific survival, but also more acute morbidity.
UT MD Anderson Cancer Center receives $12 million SPORE grant to support head and neck cancer research, focusing on genetic susceptibility markers, angiogenic therapy, and other areas. The grant aims to accelerate progress in prevention, treatment, and early diagnosis of the disease.
Researchers at Ohio State University have developed an intensification therapy regimen that combines chemotherapy and radiation to treat advanced head and neck cancers. The treatment has shown promising results, with a significant increase in survival rates and minimal patient non-compliance.
A new study found that nearly a quarter of head and neck cancer patients continue to smoke, scoring lower on quality of life measures. Depression was also prevalent among these patients, with both smoking and depression associated with significantly poorer quality of life.
A study by Dr. Jennifer Grandis and colleagues identified a protein associated with lung cancer also expressed in head and neck cancer, leading to potential therapeutic strategies. The researchers found increased GRPR expression in head and neck cancer tissues compared to healthy controls.
Two new studies published in the Journal of the National Cancer Institute suggest that frequent tomato product consumption may reduce prostate cancer risk. Additionally, researchers found a possible role for the Ras gene in neuroblastoma regression and increased levels of GRP growth factor in head and neck cancers.
A study of 114 patients with primary head and neck cancers found that photodynamic therapy achieved an overall response rate of 91% after two years, with 85% showing complete tumor elimination. The treatment also produced high one- and two-year overall survival rates of 90% and 81%, respectively.
Researchers found that human papillomavirus (HPV) is associated with a subset of head and neck cancers, particularly those of the oropharynx, which are more likely to be caused by HPV. The study also showed improved survival rates among patients with HPV-positive tumors compared to those with HPV-negative tumors.
Scientists at Johns Hopkins have developed a novel approach for detecting cancer based on genetic mutations in mitochondrial DNA. The new test uses bodily fluids such as urine, saliva, and sputum to identify cancer-specific mutations.
A new study by Duke University Medical Center found that a combination of intensive, twice-daily radiation therapy and simultaneous chemotherapy can control cancer more frequently. The treatment resulted in a significant improvement in disease control and patient survival rates.
In a Phase II study combining ONYX-015 with standard chemotherapy, nine out of ten patients experienced tumor regressions greater than 50 percent, including two complete responses. Thirty percent of patients treated with ONYX-015 alone showed significant tumor regression.
Researchers demonstrate intratumoral delivery of the E1A gene, downregulating HER-2/neu expression and tumor responses. The study shows promise for using E1A gene therapy to treat a broad range of cancers.
Researchers found that genetic variations in enzymes metabolizing drugs contribute to cancer risk, particularly head and neck cancer. Individuals with certain enzyme genotypes or histories of environmental exposures are at increased risk for cancer.
A recent study by Johns Hopkins Medicine detected genetic mutations specific to cancer in blood samples of six patients with head and neck cancer. The presence of DNA alterations in the blood was associated with large, advanced tumors and poor outcomes, including increased mortality rates.